Topic starter
There is a new scientific article that investigates whether psychedelics might potentially help with depressive complaints and negative symptoms within the schizophrenia spectrum in the future.
In it, we discuss:
Psychedelics such as psilocybin and LSD have long been studied due to their rapid and sometimes long-lasting effects on depressive symptoms. According to the authors, the interest stems in part from the fact that these substances appear to influence neuroplasticity, dopamine, glutamate, and brain networks—processes that also play a role in schizophrenia and depression.
The focus of this article is not on a new clinical breakthrough, but on the question of whether these biological effects might also be relevant to people with schizophrenia spectrum disorders. The authors describe that depressive symptoms and negative symptoms, such as reduced motivation, decreased emotional expression, and social withdrawal, partially overlap with processes that may potentially be influenced by psychedelics.
The authors also mention that preclinical research points to effects such as increased dendritic branching, increased BDNF expression, restoration of reward sensitivity, and changes in network dynamics. As a result, the idea has emerged that psychedelics might theoretically help to temporarily make rigid or dysregulated brain networks more flexible.
It is important to note, however, that this article is primarily an overview of theory, mechanisms, and early signs, and not a clinical study proving that psychedelics are already safe or effective for schizophrenia. On the contrary, uncontrolled use actually appears to be associated with more psychosis-related problems. Only a few limited case reports suggest that administration under strict control might be tolerable in carefully selected and clinically stable patients.
In one sentence: this article shows that psychedelics appear biologically promising for negative and depressive symptoms in schizophrenia, but that there is no solid clinical evidence yet and safety needs to be investigated much more thoroughly first.
Spoiler
New article description
Abstract
Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs). This narrative review summarizes mechanistic, preclinical, and early clinical findings relevant to psychedelic use in SSDs. Schizophrenia and major depressive disorder share disturbances in dopamine, glutamate, and neuroplasticity, and both involve large-scale network abnormalities. Schizophrenia is associated with widespread dysconnectivity, mesocortical hypodopaminergia, and striatal hyperdopaminergia linked to NMDA receptor hypofunction. Depression is characterized by fronto-limbic and default mode network hyperconnectivity, mesolimbic hypodopaminergia, and reduced cortical glutamatergic tone. Depressive symptoms within SSDs may reflect an intermediate phenotype combining depressive-like hyperconnectivity with schizophrenia-related global dysconnectivity, suggesting that psychedelics' capacity to transiently increase network flexibility and recalibrate maladaptive connectivity may be clinically relevant. Preclinical studies show increased dendritic spine density, enhanced BDNF expression, restored reward sensitivity, and modulation of network dynamics after psychedelic administration. Clinically, uncontrolled exposure appears associated with increased psychosis-related presentations, whereas limited case reports suggest controlled administration may be tolerated in carefully selected, clinically stable individuals with SSDs. To date, only one early-phase trial (MDMA in schizophrenia) is ongoing, and no randomized trials have evaluated psilocybin or LSD in SSDs. Overall, psychedelics are biologically and mechanistically plausible but remain unproven for depressive and negative symptoms in SSDs, which partially overlap. Carefully designed, safety-focused early-phase studies in clinically stable patients are therefore a prerequisite for broader clinical application.
Keywords: Psychedelics; schizophrenia spectrum disorder; negative symptoms; depressive symptoms; neuroplasticity; psilocybin; LSD; MDMA.
Posted : 18 March 2026 14:20